Which dyskinesia scale best detects treatment response?

Area of Science:

• Neurology
• Movement Disorders
• Clinical Pharmacology

Background:

• Parkinson's disease (PD) is frequently associated with dyskinesia, a common and disabling side effect of dopaminergic therapy.
• Numerous scales exist to quantify dyskinesia, but their comparative efficacy in detecting treatment-induced changes remains unclear.
• Establishing a reliable and sensitive scale is crucial for evaluating novel anti-dyskinetic therapies.

Purpose of the Study:

• To compare the sensitivity of eight different scales in detecting treatment-related changes in dyskinesia in Parkinson's disease.
• To identify the most effective scale for assessing the efficacy of amantadine, an established anti-dyskinetic agent, in a randomized placebo-controlled trial.

Main Methods:

• A randomized, placebo-controlled trial involving 61 participants with dyskinetic PD was conducted.
• Participants were assessed at baseline, 4 weeks, and 8 weeks using eight distinct dyskinesia rating scales, including the Unified Dyskinesia Rating Scale (UDysRS), Lang-Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), and others.
• Sensitivity to treatment was evaluated using effect size calculations, with the UDysRS Total Score showing the highest effect size.

Main Results:

• Four scales (Clinical Global Impression-Change [CGI-C], LF, 26-Item Parkinson's Disease Dyskinesia scale [PDD-26], and UDysRS) significantly detected treatment effects.
• The UDysRS Total Score exhibited the largest effect size (η(2) = 0.138), indicating superior sensitivity in detecting changes related to amantadine treatment.
• No scale demonstrated complete resistance to placebo effects.

Conclusions:

• The Unified Dyskinesia Rating Scale (UDysRS) is the most sensitive and effective scale for detecting treatment-induced changes in dyskinesia in Parkinson's disease patients.
• The UDysRS, incorporating both subjective and objective measures, provides a robust assessment of dyskinesia.
• The established effect size of the UDysRS with amantadine provides a benchmark for future anti-dyskinetic drug trials.